We’re delighted to announce the expansion of the Symbiosis Business Development team with the addition of two highly experienced U.S. Business Development Directors: Jacqueline Towell (above left), who will oversee the US West Coast region, and Cindy Koonce (above right), who will focus on the US East Coast.
Both Jacqueline and Cindy bring a wealth of expertise from the pharmaceutical and biotechnology sectors, further strengthening the business’ ability to support clients across North America and reinforcing our commitment to providing high-quality, rapid-turnaround fill-finish manufacturing services for biopharmaceutical products.
Jacqueline joins Symbiosis with over 12 years of experience in the Contract Development and Manufacturing Organization (CDMO) space, having worked at leading firms including Alcami, Patheon and Pii.
Based in Southern California, her role will focus on driving business development and managing strategic accounts in the US West Coast region.
“My background in technical solutions, client relationship management, and contract negotiations will be instrumental in continuing Symbiosis’ growth and solidifying its position within the expanding biologics and advanced therapies market” said Jacqueline.
“I will be using my expertise to enhance Symbiosis’ ability to meet the increasing demand for high-quality drug product manufacturing, especially for biologics, advanced therapies, and gene-based medicines. These are exciting times!”
Cindy, based in Wilmington, NC, brings over 20 years of business development experience in the pharmaceutical industry, having held roles at Alcami, Pii and most recently Infinity Laboratories.
Cindy will focus on the US East Coast region, where her responsibility will be to drive new business opportunities and managing existing client relationships. She added: “I have a customer-centric approach and a deep understanding of the industry – both of which align perfectly with Symbiosis’ goal of offering outstanding customer service and high-quality manufacturing solutions”.
Both appointments come at a key time for our growth strategy, as the company continues to expand with a new state-of-the-art automated sterile manufacturing facility, close to our existing facilities in Stirling, Scotland, and set to be fully commissioned in early 2025 following regulatory inspection. This will increase our commercial scale sterile manufacturing capabilities, enabling us to serve a growing global client base.
“These appointments are a testament to our ongoing commitment to supporting our clients and growing our presence in the North American market”, comments Colin MacKay, CEO of Symbiosis.
“Both Jacqueline and Cindy bring valuable industry experience and a track record of success in business development. Their expertise will allow us to unlock new opportunities and better serve our clients in key regions, while continuing to expand our capabilities globally”.
The expansion of Symbiosis’ business development team reflects the broader strategy of enhancing our client relationships, driving business growth, and meeting the increasing demand for our GMP manufacturing services in the biopharmaceutical sector.
To book an appointment with either Cindy or Jacqueline, click here
